Our previous studies have investigated the systematic pharmacokinetic characteristics, biological activities, and toxicity of arctigenin. In this research, the potential toxicities of arctigenin in beagle dogs were investigated via repeated 28-day subcutaneous injections. Beagle dogs were randomly divided into control, vehicle [polyethylene glycol (PEG)], and arctigenin 6, 20, 60 mg/kg treated groups. The whole experimental period lasted 77 days, including adaptive period (35 days), drug exposure period (animals were treated with saline, PEG, or arctigenin for 28 consecutive days), and recovery period (14 days). Arctigenin injection (60 mg/kg) affected the lymphatic hematopoietic, digestive, urinary, and cardiovascular systems, and all the impact on these tissues resulted in death in five dogs (three female and two male dogs); 20 mg/kg arctigenin injection resulted in toxic reactions of the lymphatic hematopoietic and digestive systems; and 6 mg/kg arctigenin and PEG injection did not lead to significant toxic reactions. Meanwhile, there were no sexual differences of drug exposure and accumulation when dogs underwent different dosages. As stated previously, the toxic target organs of arctigenin administration include lymphatic hematopoietic, digestive (liver and gallbladder), urinary (kidney), and cardiovascular (heart) systems, and the no observed adverse effect level (NOAEL) of arctigenin is less than 6 mg/kg.
INTRODUCTION
Greater burdock (Arctium lappa) is widely known as niubang in China, and was introduced into Japan and Korea, and widely eaten in the region (Baba et al., 2018; Lee et al., 2018) . During the Middle Ages, it was used in Europe as a vegetable, and even now, it is still used in Italy, Brazil, and Portugal (Miguel et al., 2010; Meinhart et al., 2017) . In addition, the root of burdock was traditionally used in Britain as a flavoring in the herbal drink made with dandelion and burdock, and is still commercially produced (Watkins et al., 2012) . In the 20 th century, burdock was advocated in culinary use due to the increasing popularity of the macrobiotic diet.
Arctigenin, the aglycone of arctiin, was found in greater burdock and was reported to have antiviral (Chen et al., 2016; Dias et al., 2017) and anticancer (Jiang et al., 2015; Feng et al., 2017) effects in vitro. In a mouse model of Japanese encephalitis, arctigenin showed effective function (Swarup et al., 2008) . Further, arctigenin was reported to act as an agonist of adiponectin receptor 1 (AdipoR1) (Sun et al., 2013) . Our previous study investigated the systematic pharmacokinetics of arctigenin in rats and beagle dogs . The results showed that compared with oral administration, subcutaneous injection of arctigenin exhibited a strong absorption capacity in beagle dogs (absorption rate < 1 h), a high absorption degree (absolute bioavailability > 100%), and a strong elimination ability (t 1/2 < 2 h). Subsequently, another study investigated the efficacy and potential mechanism of arctigenin on liver cancer (Sun et al., 2018) . Our results have shown that arctigenin significantly inhibited cell growth, migration, invasion, and colony formation of HepG2 cells via reduction of the gankyrin expression in both mRNA and protein.
Although multiple bioactivities of arctigenin were found in vivo and in vitro (Wu et al., 2014; Liu et al., 2015; Su et al., 2015; Huang et al., 2017) , the systemic evaluation of this chemical's toxicology was rarely reported. In the present research, the potential toxicities of arctigenin in beagle dogs were investigated via repeated 28-day subcutaneous injection. The characteristics, degrees, dose effects, time effects, and reversibility of toxic reactions and the target organs or tissues after arctigenin exposure were investigated.
MATERIALS AND METHODS

Chemicals and Agents
Arctigenin injection (purity was 99.8%, 500 mg/10 ml, Cat. #120801) and polyethylene glycol (PEG) solution (80%, Cat. #120804) were supplied by Shandong New Time Pharmaceutical Co. (Linyi, Shan Dong province, China). The chemical structure of arctigenin is shown in Figure 1 . The saline (0.9% NaCl, Cat. #M12101307) was purchased from Kelun Pharmaceutical Co. (Chengdu, Sichuan Province, China) . Pentobarbital sodium was from Sigma-Aldrich (Cat. #93ET2904K, St. Louis, MO, USA).
Test Article Solutions Analysis
Before the first drug exposure, the relative errors (RE) between measured concentrations and theoretical value of fresh solutions of arctigenin (6 mg/kg, 20 mg/kg, and 60 mg/kg) were 13.2%, 10.8%, and 7.5%, respectively. The upper, middle, and lower solution's relative standard deviations (RSD) were 3.7%, 0.5%, and 1.7%, respectively.
On the day of drug exposure, the RE between measured concentrations and theoretical value of first fresh solutions of arctigenin (6 mg/kg, 20 mg/kg, and 60 mg/kg) were −3.9%, −3.0%, and −1.9%, respectively. The upper, middle, and lower solution's RSDs were 2.8%, 1.2%, and 3.3%, respectively.
On the day of last drug exposure, the RE between measured concentrations and the oretical value of first fresh solutions of arctigenin (6 mg/kg, 20 mg/kg, and 60 mg/kg) were 9.7%, 15.2%, 
Body Weight and Food Consumption
The body weight in all groups was measured once before the first drug exposure and then measured twice per week (on Monday and Thursday) during the drug exposure period and then measured weekly (on Thursday) during the recovery period. Food consumption was measured on one day each week over a 24-h period. On the days of the food consumption assays, 300 g animal feed was delivered, and the remaining portions were measured at the same time on the second day (on Monday), and the food consumption was calculated.
Rectal Temperature
The rectal temperatures of all animals were recorded before drug administration and at 1, 4, and 24 h after the first drug exposure. On experiment days 14 and 27, temperatures were recorded 1 h after drug injection. Rectal temperatures were measured using a TH-212 digital thermo detector (Cat. #TH-212, Beijing hightech Co. Beijing, China).
Electrocardiogram (Ii Lead)
Electrocardiograms (II lead) were performed using a fourchannel polygraph (Cat. #RM6240, Chengdu Instrument Factory, Chengdu, Sichuan province, China) before and at 1, 4, and 24 h after the first drug exposure; before and at 1 h after drug exposure at day 14; before and at 1 and 2 h after drug exposure on day 20; and before and at 1 h after drug exposure on day 27.
Ophthalmic Examination
At the end of drug exposure (day 27) and recovery (day 42), tropicamide was applied to the mydriasis, cornea, iris, crystalline lens, anterior/atria chamber, and fundus oculi of all animals, and they were examined using the Binocular Indirect Ophthalmoscope (Cat. #YZ25A, 6-6 VISION TECH Co., Ltd., Suzhou, Jiangsu province, China).
Hematologic, Biochemical, and Cardiac Troponin (ctn-T) Examination
Before drug exposure on days 3, 14, and 27, the forelimb vein blood (4.9 ml) was collected from all animals, who fasted for 12 h before sampling.
For hematological cytology assay, 1 ml of blood was anticoagulated by ethylenediamine tetraacetic acid (EDTA). For detecting clotting time, 0.9 ml of blood was anticoagulated by sodium citrate, 1800g for 10 min at room temperature (RT), and the plasma was separated for examination. Hematological parameters including red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), reticulocyte (RET%), white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MONO), eosinophils (EOS), basophils (BASO), platelets (PLT), prothrombin time (PT), and activated partial thromboplastin time (APTT) were detected by the Automatic Five Classification Blood Analyzer (ADVIA2120, SIEMENS, Germany) and the Automatic Hemagglutination Analyzer (CA-7000, SYSMEX, Japan), respectively.
For biochemical examination, 3 ml of blood was centrifuged (1800g, 10 min, RT), and serum was prepared for examination. Parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK), myocardial bound creatine kinase (CK-MB), alkaline phosphatase (ALP), L-lactate dehydrogenase (LDH), γ-glutamyl transpeptidase (GGT), urea (urea), troponin (TP), albumin (ALB), albumin/ globulin (A/G), glucose (GLU), total bilirubin (TBIL), creatinine (crea), cholesterol (CHOL), triglyceride (TG), amylopsin (AMY-P), lipidase (LIPC), calcium (Ca), P, sodium (Na + ), potassium (K + ), and chloride ion (Cl − ) were detected by Automatic Blood Biochemical Analyzer (Cobas C501, ROCHE, Switzerland).
For cardiac troponin (cTn-T) examination, 1 ml of blood was centrifuged (1800g, 10 min, RT), and serum was prepared for examination.
Urine and Feces Examination
Urine and feces examinations were conducted once on days 13 and 29 and at the end of the recovery period. Urine parameters including glucose (GLU), bilirubin (BIL), ketones (KET), specific gravity (SG), occult blood (BLO), pH, protein (PRO), urobilinogen (URO), nitrogen (NIT), and WBC were detected by Urine Analyzer (CLINITEK STATUS, BAYER, Germany).
Bone Marrow Slides Examination
Bone marrow slide examinations were conducted once on day 29 and at the end of the recovery period. The beagle dogs were anesthetized by pentobarbital sodium (30 mg/kg intravenous), bone marrow was stained by Wright-Giemsa, and parameters including granulocyte series, erythrocyte series, lymphocyte series, monocyte series, megakaryocyte, and karyocyte were evaluated.
Toxicokinetics Study
From 0 min to 8 h after arctigenin administration, 1 ml of the dogs' forelimb vein blood was obtained. The blood samples were centrifuged at 3000 rpm for 10 min at 4°C to obtain the plasma (45 μl). After adding 5 μl internal standard (IS) and 145 μl methanol, centrifuging at 10,000 rpm for 10 min at 4°C, and repeating this step once to obtain the supernatant, 100-μl samples were collected, and arctigenin concentrations were detected by HPLC-MS/MS. Kinetic parameters (AUC 0-t , C max , and T max ) were calculated.
Autopsy and Histopathology Examination
The autopsy was conducted at the end of the drug exposure (on day 29, four dogs per group were autopsied) and at the recovery period (the remaining dogs: four in control, PEG, and arctigenin 6 mg/kg groups; four in arctigenin 20 mg/kg group; and one in arctigenin 60 mg/kg group). The brain, spleen, thymus, lung, heart, liver, testis (bilateral)/ovaries (bilateral), kidneys (bilateral), and adrenal glands (bilateral) were separated and weighed. KET, ketones; PRO, protein; BIL, bilirubin; URO, urobilinogen; NIT, nitrite; S.G, specific gravity; LEU, leucocytes; B.W, body weight; P-R inter , P-R intermittent; HR, heart rate;
To detect tissue injury, the histopathology examination was performed as previously described (Akindele et al., 2014) . In brief, dog tissues were fixed in 4% paraformaldehyde buffer for 24 h, dehydrated in graded alcohol (70, 90, 95, and 100%) , and embedded in paraffin. Subsequently, paraffin blocks were cut into 2-µm sections and then subjected to routine hematoxylin-eosin (H&E) staining according to previous protocols (Fei et al., 2017) . The photomicroscopic assessment using BX53 photomicroscope (Olympus, Tokyo, Japan) and the histopathology slides were viewed at various magnifications (×40, ×100, and × 400) to detect pathological lesions.
Statistical Analysis
Data were calculated and analyzed with Excel 2010 (Microsoft, Redmond, WA, USA) and SPSS V19.0 (SPSS, Inc., Chicago, IL, USA). Toxicokinetic parameters, including C max , T max , and area under the curve (AUC), and the compartment model were analyzed by the Drug and Statistics (DAS) 3.0 software (Chinese Mathematical Pharmacology Society, Beijing, China). All values were presented as mean ± standard deviation (S.D.) and calculated using an unpaired t test by SPSS Statistics V19.0.
RESULTS
Death/Articulo Mortis of Animals
At the beginning of the drug exposure period, one animal in the arctigenin 60 mg/kg group (female, NO. 5F04) had onset of symptoms, including loose stools, pronation, and feeding reduction. After seven consecutive days of drug exposure, convulsion, respiratory slow down, deeper breathing, and limb rigidity, and, subsequently, death were observed in this animal. Four animals in the arctigenin 60 mg/kg group (two females and two males, NO. 5M04, 5F02, 5F03, and 5M01) showed activity and feeding reductions after the first drug exposure, and from day 8 to day 14 of drug exposure period. All these animals presented pronation, myasthenia of limbs, magersucht, yellow skin, dark red diarrhea, respiratory slow down, deeper breathing, and articulo mortis on days 20, 22, 23, and 26, respectively. As shown in Table 1 , four animals in articulo mortis presented hemopoiesis inhibition (erythron index reduction, reticulocyte ratio increase), abnormal liver function index (ALP, ALT, AST, LDH, TBIL), electrolyte disturbances (K + , Cl − ), clotting time prolongation (APTT, PT), and abnormal kidney function (crea, urea, urine glucose, occult blood, urobilinogen) ( Table 2) .
The electrocardiogram examination demonstrated that the animals in articulo mortis showed sinus arrhythmia, a reduced heart rate, P-wave and Q-wave disappearance, S-T and T wave elevation, and Q-T interval prolongation (Table 1, Figure S1 ). All these results implied that myocardial damage obstruction may have occurred in these animals.
The histopathological results showed test article subcutaneous deposition at the injection site, mammary gland, and subaxillary lymph node, which resulted in moderate-severe inflammation and foreign body reaction, including edema, hemorrhage, necrosis, and inflammatory cell infiltration. In the lymphatic hematopoietic system, subaxillary lymph node lesions appeared with mild-moderate red cell increase/phagocytosis (two of three dogs) and mild pigmentation in the lymphoid sinus (one of three dogs). In the spleen, one dog (1/5) had moderate extramedullary hematopoiesis (EMH); mild-moderate foam-like macrophage aggregation was observed in three dogs (3/5); and mild white pulp atrophy was observed in two dogs (2/5). In the thymus, two dogs (2/3) showed marked-severe atrophy. In the digestive system, the liver in five dogs showed mild-marked hepatocyte degeneration/necrosis, minimal-slight cholestasis in four dogs (4/5) (Figure 2A) , and minimal inflammatory cell infiltration and nuclear mitosis in three dogs (3/5) ( Figure 2B ). Mucous epithelial hyperplasia was observed in one dog's gall bladder. In addition, three dogs' pancreas presented minimal acinus hypertrophy. Lesions in the urinary system occurred mainly in the kidneys (slight-moderate nephrosis), such as pigmentation and basophilic changes (Figure 2C) , nuclear division ( Figure 2D ) in the renal tubular epithelial cells, renal tubule dilatation ( Figure  2E) , and transparent droplets in the bowman capsule ( Figure 2F ). In addition, pigments were observed in one dog's bladder.
The respiratory system injuries included moderate pneumonedema (1/5), and macrophages accumulated in pulmonary vessels (1/5). Moderate hemorrhage (1/5) and slight myocardial/interstitial vacuolation (1/5) were observed in the heart, and mild hemorrhage of the aorta occurred in one dog (1/5). Three female dogs' uterus (3/3) and two dogs' testis, epididymis, and prostate were immatured.
All these results demonstrated that 60 mg/kg/day arctigenin administration induced one dog death, and that the four cases of articulo mortis may have resulted from marked liver and renal injuries. In addition, one female dog (5F02) showed heart and aorta hemorrhage, and one (5F03) showed pneumonedema and macrophages accumulated, which may have resulted in articulo mortis.
General Observation
During the drug exposure and recovery periods, animals in the control group were in good condition, with normal autonomic activities, clean coats, and no obvious toxicities. In the vehicle (PEG) group, growling, struggling, and occasional vomiting were observed during the drug exposure period. At the middle and end of the drug exposure period, animals' skin presented with partial induration, damage, and escharosis at the injection site. All these symptoms were alleviated after the recovery period. In addition to these symptoms, 20-and 60-mg/kg/day administration in dogs resulted in sialorrhea; squatting; mental sluggishness; low food consumption; and trauma, ulceration, and escharosis the injection site. After the recovery period, all but ulcerations and escharosis still remained in the 20-and 60-mg/kg/day arctigenin treated groups, and the other dogs' injuries resolved with no significant toxicities.
Body Weight, Food Consumption, and Rectal Temperature
Compared with the control group, the group that received 60 mg/kg/day arctigenin had significantly decreased body weights (7.96 ± 1.02 kg vs. 9.15 ± 0.53 kg) in the third week of the drug exposure period, and the difference was eliminated after the recovery period ( Figure S2A ). In addition, the body weights among the PEG group, the arctigenin 6 mg/kg group, and the arctigenin 20 mg/kg group were not significantly different during the drug exposure and recovery periods ( Table 3) .
The amount of food consumption was not different among the groups throughout the whole experiment period (p > 0.05). The arctigenin 60 mg/kg/day group's food consumption showed a downward trend, but returned to normal after the recovery period ( Figure S2B , Table 4 ).
Compared with the control group, the rectal temperature was decreased in the arctigenin 6 mg/kg/day treated group (38.2± 0.1°Cvs. 38.5 ± 0.2°C. Figure S2C , Table 5 ). However, this fluctuation was in the normal range and not dose-dependent.
In all five groups, the only death occurred in the arctigenin 60 mg/kg/day treated group (five dogs died, including one death and four articulo mortis). The survival percentage is shown in Figure S2D .
Electrocardiogram
Compared with the control group, the dogs in the PEG group, arctigenin 6 mg/kg, and arctigenin 60 mg/kg group showed Q-T intermittent and shortened intervals on II lead electrocardiogram before day 14. In addition, P-wave and QRS-wave time shortened In arctigenin-60 mg/kg treated group, four animals died (5F04/5F02/5F03/5M01) after drug exposure. in the arctigenin 60 mg/kg treated group. However, 1 h after drug administration on day 14, all arctigenin-treated groups showed P-wave shortening. Further, 1 h after drug administration on day 20, the Q-T intermittent and correction Q-T interphase were prolonged in the arctigenin 60 mg/kg group, and P-wave altered in the arctigenin 20 mg/kg group. On day 27 (before drug exposure), the heart rates were elevated in the arctigenin 60 mg/ kg group compared with the control group ( Table 6 ).
The P-wave alterations were within normal ranges (within 25%), and no significant differences were found before and after drug administration. In addition, all parameters including electrocardiographic wave, HR, RR, P, PR, QRS, QT, and correction Q-T had no differences among the 1 st , 14 th , 20 th , and 27 th day of drug exposure (p > 0.05).
Hematology Examination
To investigate the potential influence of sub-chronic arctigenin administration on hematology, the parameters including RBC, HGB, HCT, MCV, MCH, MCHC, RET%, WBC, NEU, LYM, MONO, EOS, BASO, PLT, PT, and APTT were detected on days 3, 14, 27, and in the recovery period. The details of the results are shown in Table 7 . In the early stage of the experiment (day 3), WBC, NEU, NEU%, MONO, and LYM% were elevated, and EOS%, HGB, and HCT% were reduced in the arctigenin 60 mg/kg group, compared with the control group. In the middle stage (day 14), WBC was elevated in the PEG group, WBC and NEU were elevated in the arctigenin 6 mg/kg group, and WBC, MOMO, and PLT were elevated in the arctigenin 20 mg/kg group. In addition, WBC, NEU, NEU%, MOMO, LYM%, and PLT were elevated, and PT was prolonged, in the arctigenin 60 mg/kg group. In the later stage (day 27), WBC was elevated in the PEG and arctigenin 6 mg/kg groups, and WBC, MOMO, and PLT were elevated in the arctigenin 20 mg/ kg group. In addition, WBC, LYM, MOMO, RET% were elevated, HCT% and MCHC were decreased, and PT was prolonged in the arctigenin 60 mg/kg group. After a 14-day recovery period, only elevated PLT was observed in the arctigenin 20 mg/kg group.
Blood Biochemical Examination
Compared with the control group at the same time point, PEG treatment induced a decrease in TBIL at day 27. However, arctigenin administration resulted in a series of changes as follows: 1) On day 3, CK increased, and TBIL and K + decreased by arctigenin 6 mg/ kg treatment; GLU and Cl − increased, and AST, CK-MB, LDH, and CHOL decreased by arctigenin 20 mg/kg treatment; GLU and Cl − increased, and AST, GGT, CK-MB, LDH, urea, crea, TP, ALB, TBIL, K + , Ca, and AMY-P decreased by arctigenin 60 mg/ kg treatment. 2) On day 14, K + decreased by arctigenin 6 mg/kg treatment; ALP, ALT, AST, and Cl − increased, and ALB decreased by arctigenin 20 mg/kg treatment; ALP, ALT, and AST increased, and crea, TP, ALB, CHOL, K + , Ca, and P decreased by arctigenin 60 mg/kg treatment. 3) On day 27, TBIL decreased by arctigenin 6 mg/kg treatment; ALP, ALT, AST, and GGT increased; ALB and CHOL decreased by arctigenin 20 mg/kg treatment; ALP, ALT, AST, GGT, LDH, TBIL, Cl − , and LIPC increased, and crea, TP, ALB, A/G, CHOL, Ca, and AMY-P decreased by arctigenin 60 mg/ kg treatment. 4) At the end of the recovery period, crea and ALB were reduced by arctigenin 20 mg/kg treatment. Combined with individual parameters, the amplitude of TP, K + , Cl − , Ca, P, AMY-P, crea, and ALB variations was less than 35%, and was not time-and dose-dependent, which suggests that all these changes were within normal limits. In contrast, ALP, ALT, AST, and GGT were significantly increased and CHOL was decreased by 20 mg/kg treatment. ALP, ALT, AST, TBIL, GGT, and LIPC were significantly elevated and ALB and A/G were decreased by 60 mg/kg treatment. These changes were time-and dose-dependent, which suggests that they may have resulted from arctigenin administration. In addition, there were no differences in any of the parameters during the drug exposure and recovery periods. The data are shown in Table 8 .
Urine and Faces Examination
Compared with the control group at the same time point, arctigenin administration resulted in series of changes as follows: 1) On day 13, BLO was significantly increased in both the arctigenin 20 and 60 mg/kg treated groups (p < 0.5). 2) On day 29, GLU, BIL, and URO were increased in the 60 mg/kg treated groups (p < 0.5). Otherwise, all urine parameters were no different, either at a different period or at a different dosage ( Table 9) . The feces of all animals were studied during the drug exposure and recovery periods. The color, parasites, RBC, WBC, epithelial cells, fat granules, and BLO showed no differences among all groups ( Table 10) .
ctn-T and Bone Marrow Examination
Compared with the control group at the same time point (drug exposure and recovery period), neither PEG nor arctigenin treatment resulted in a cTn-T index change (data not shown).
At the end of the recovery period, the percentage of other cells in the PEG-treated group was elevated (p < 0.05). In addition, compared with the control group, the parameters of bone marrow smears were no different among all the animals (Table 11) .
Viscera Weights and Viscera/Body Weights Index
Compared with the control group, neither the PEG group nor the arctigenin-treated group had changes in viscera weights and viscera/body weights of heart, liver, spleen, lung, kidney, brain, adrenal glands, ovary, uterus, testis, and epididymis (p > 0.05). However, at the end of the drug exposure period, one dog's kidney weight and kidney/body weight index were both increased by arctigenin 20 mg/kg treatment (4M02). In the arctigenin 60 mg/kg treatment group, viscera weights and viscera/body weights of the spleen (5F01) and kidney (5F01, 5M03) were increased at the end of drug exposure, and all animals' ovary, uterus, testis, and epididymis weights were decreased after the recovery period (Table 12 ).
Toxicological Study
To determine its toxicokinetic characteristics, the plasma concentration-time profiles of arctigenin were detected following subcutaneous administration of 6, 20, and 60 mg/kg arctigenin in beagle dogs (Figure S3) , and the TK parameters are shown in Table S1 . After drug administration, the average values of T max were 75 to 195 min and 67.5 to 240 min after the first and the last drug exposure by subcutaneous injections, respectively (Table S1) .
After the first drug exposure, the ratios of female and male plasma AUC 0-t were 1:3.2: 8 and 1:2.7:5.9 when animals underwent different dosage administration (6, 20, and 60 mg/kg ratio was 1:3.3:10). In addition, these ratios were changed to 1:3.8:11.8 and 1:4.9:12.3 after the last drug exposure, respectively. AUC last showed no difference compared with AUC first in both male and female dogs, and the ratio of AUC last /AUC first was 0.9:1.9, which suggested that there was no drug accumulation (Figure S4) .
Pathological Examination
Gross anatomy. 1) After drug exposure, injection sites were observed as dark red in all animals (including PEG-and arctigenintreated animals). In two dogs in the PEG group (2/4), one dog in the arctigenin 6 mg/kg group (1/4), one dog in the arctigenin 20 mg/kg group (1/4), and one dog in the arctigenin 6 mg/kg group (1/2), volume enlargement of the subaxillary lymph node was observed. Further, arctigenin treatment (both 20 and 60 mg/kg) resulted in testicular and epididymal volume reduction. Arctigenin 60 mg/kg injection led to liver and spleen volume enlargement, uterine volume reduction, and pancreatic swelling. 2) After the recovery period, dark red was still observed subcutaneously at the injection site in the PEG group (four dogs, 4/4), the arctigenin 6 mg/kg group (three dogs, 3/4), the arctigenin 20 mg/kg group (four dogs, 4/4), and the arctigenin 60 mg/kg group (one dog, 1/1). Furthermore, 60 mg/kg arctigenin administration resulted in a reduction in the dogs' thymus volume.
Histopathology Examination. 1) After drug exposure, slightsevere, moderate-severe, moderate-severe, and severe-serious test articles deposition/inflammation were observed in the PEG group (four dogs, 4/4), the arctigenin 6 mg/kg group (four dogs, 4/4), the arctigenin 20 mg/kg group (four dogs, 4/4), and the arctigenin 60 mg/kg group (two dogs, 2/2), respectively. Compared with the control group, the primary pathological changes of drug exposure sites were drug subcutaneous deposition, foreign body giant cell responses, extensive edema, bleeding, necrosis, and inflammatory cell infiltration. In addition, in the arctigenin 60 mg/kg treatment group, a foreign body response was observed in one dog's subcutaneous tissue of the mammary gland, which may have resulted from the spread of the series of pathological changes at the drug exposure site. In the lymphoid hematopoietic system, test article subcutaneous deposition at the subaxillary lymph node was observed in the PEG group (slight, two dogs, 2/4), the arctigenin 6 mg/kg group (slight, two dogs, 2/4), the arctigenin 20 mg/kg group (slight-moderate, three dogs, 3/4), and the arctigenin 60 mg/kg group (slight-moderate, two dogs, 2/2). In addition, slight-severe red cells increased/phagocytosed in the sinus. In the thymus, arctigenin 20 and 60 mg/kg administration resulted in slight-severe thymus atrophy. In the spleen, arctigenin 60 mg/kg administration caused severe EMH, slight foamlike macrophage aggregation, and white pulp atrophy. In the digestive system, hepatocyte degeneration/necrosis, cholestasis, and inflammatory cell infiltration were observed in both the arctigenin 20 and 60 mg/kg group (Figure 3A, B) . In addition, arctigenin 60 mg/kg exposure resulted in EMH and increased nuclear mitosis (Figure 3C) . Furthermore, both arctigenin 20 and 60 mg/kg treatment caused slight mucous epithelial hyperplasia of the gallbladder, and slight pancreas acinus hypertrophy combined with interstitial edema resulted from arctigenin 60 mg/kg administration. In the urinary system, moderate renal tubular basophilic degeneration/regeneration, pigmentation, and hyaline droplets in the Bowman capsule of the renal tubules were observed in the arctigenin 60 mg/kg group (Figure 3D-F) .
Besides that, slight EMH of the adrenal glands was caused by arctigenin 60 mg/kg administration. 2) After the recovery period, the pathological changes of drug exposure sites in all treatment animals (including PEG-and arctigenin-treated groups) were observed including drug subcutaneous deposition, foreign body giant cell responses, and extensive fibroplastic proliferation, which were significantly ameliorated in PEG, arctigenin 6, and arctigenin 20 mg/kg treatment groups after the 14-day recovery, but not in the arctigenin 60 mg/kg treated animals. In accordance with the injection sites, slight-moderate test articles deposition and pigmentation of the subaxillary lymph node were observed in the arctigenin administration groups (including 6, 20, and 60 mg/ kg). Arctigenin 20 mg/kg treatment resulted in submaxillary lymph node deposition/foreign body reaction. In the spleen, even after recovery, slight and severe EMH and foam-like macrophage aggregation still existed in the PEG group, the arctigenin 20 mg/ kg group, and the arctigenin 60 mg/kg group. Although thymus atrophy was improved in the control and PEG treated groups, severe and slight thymus atrophy remained in the arctigenin 20 and 60 mg/kg groups. In addition, slight-moderate cholestasis, slight hepatocyte degeneration/necrosis, inflammatory cell Frontiers in Pharmacology | www.frontiersin.org TABLE 12 | Viscera weights and viscera/body weights index of arctigenin (6, 20, and 60 mg/kg) administration by i.h in beagle dogs at the end of drug delivery (n = 4, 2 male and 2 female) and recovery period (n = 4, 2 female, 2 male per treatment group; results were presented as mean ± S.D.). be completely dissolved in PEG400. In this study, both PEG-and arctigenin-treated groups were given high concentration (80%) and volume (1.2 ml/kg) of PEG-400 as a solvent for consecutive 28-day injections, which resulted in obvious stress reactions as follows. 1) During the drug administration, the symptoms such as growling, struggling, and vomiting were observed in dogs, and repeated biting by dogs of the injection sites resulted in trauma, ulceration, and scabbing. 2) Compared with PEG, arctigenin induced local hemolysis, and WBC increases were more significant, especially in the arctigenin 60 mg/kg group, and the subchronic administration resulted in an increase of RET%, a decrease in coagulation function (PLT and PT prolonged), and a decrease in ALB and A/G. 3) Varying degrees of deposition/inflammation of dogs' subcutaneous reactions, foreign body reactions, and polycythemia of dogs' lymph nodes were observed in PEG-and arctigenin-treated groups by histopathology examinations. All these abnormal hematological, biochemical, and histopathological changes were associated with the dosage of arctigenin. However, after the 2-week recovery period, hematological and biochemical parameters were not abnormal, and pathological symptoms were relieved. The main toxic target organs of PEG and/ or arctigenin include hematopoietic, digestive, and urinary systems. Effects of arctigenin on lymphatic hematopoietic system including WBC and PLT elevation, macrophage accumulation in spleen, thymus atrophy, and so on were caused by inflammation at the injection sites. In addition, toxicity of arctigenin on digestive system, e.g., liver enlargement, degeneration and necrosis, pancreatic cysts, and cholestasis, is the main reason of dogs' death. Indicators of urine routine were significantly elevated and renal tubule was basophilic or regenerative after 60 mg/kg arctigenin treatment, which was related to a hemolytic reaction in the kidney. Arctigenin (60 mg/kg) also influenced dogs' lung and heart. There inflammation happened after arctigenin treatment. These data supplied a reference for clinical trial and drug registration. Due to the limits of arctigenin's poor oral bioavailability, subcutaneous injected administration was selected. Toxicity of arctigenin by oral administration after drug formulation change will be researched in the future.
Parameters
CONCLUSION
This study provides a systematic investigation of the toxic profiles of arctigenin in vivo. In summary, the no observed adverse effect level (NOAEL) of arctigenin was less than 6 mg/kg in dogs, which corresponded to human dose 3.21 mg/kg. This result provides a reference for the safety of arctigenin at a clinical trial. The main targets of arctigenin toxicities were heart, liver, and kidney. Hepatocyte necrosis, renal tubular degeneration, and cardiotoxicity are the leading reasons of death.
